185 related articles for article (PubMed ID: 1416834)
1. Effects of antibiotics and other drugs on toxin production in Clostridium difficile in vitro and in vivo.
Barc MC; Depitre C; Corthier G; Collignon A; Su WJ; Bourlioux P
Antimicrob Agents Chemother; 1992 Jun; 36(6):1332-5. PubMed ID: 1416834
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxin and enterotoxin production by Clostridium difficile.
Gianfrilli P; Luzzi I; Pantosti A; Occhionero M; Gentile G; Panichi G
Microbiologica; 1984 Oct; 7(4):375-9. PubMed ID: 6513801
[TBL] [Abstract][Full Text] [Related]
4. Epidemic ribotypes of Clostridium (now Clostridioides) difficile are likely to be more virulent than non-epidemic ribotypes in animal models.
Vitucci JC; Pulse M; Tabor-Simecka L; Simecka J
BMC Microbiol; 2020 Feb; 20(1):27. PubMed ID: 32024477
[TBL] [Abstract][Full Text] [Related]
5. Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A.
Cowardin CA; Jackman BM; Noor Z; Burgess SL; Feig AL; Petri WA
Infect Immun; 2016 Aug; 84(8):2317-2323. PubMed ID: 27271747
[TBL] [Abstract][Full Text] [Related]
6. Both, toxin A and toxin B, are important in Clostridium difficile infection.
Kuehne SA; Cartman ST; Minton NP
Gut Microbes; 2011; 2(4):252-5. PubMed ID: 21804353
[TBL] [Abstract][Full Text] [Related]
7. Concurrence of Clostridium difficile toxin A enzyme-linked immunosorbent assay, fecal lactoferrin assay, and clinical criteria with C. difficile cytotoxin titer in two patient cohorts.
Schleupner MA; Garner DC; Sosnowski KM; Schleupner CJ; Barrett LJ; Silva E; Hirsch D; Guerrant RL
J Clin Microbiol; 1995 Jul; 33(7):1755-9. PubMed ID: 7665642
[TBL] [Abstract][Full Text] [Related]
8. Effect of toxins produced by various Clostridium difficile strains on cecum size reduction in gnotobiotic mice.
Mahé S; Corthier G
Can J Microbiol; 1988 Jul; 34(7):916-8. PubMed ID: 3143476
[TBL] [Abstract][Full Text] [Related]
9. Toxigenic Clostridium difficile colonization among hospitalised adults; risk factors and impact on survival.
Behar L; Chadwick D; Dunne A; Jones CI; Proctor C; Rajkumar C; Sharratt P; Stanley P; Whiley A; Wilks M; Llewelyn MJ
J Infect; 2017 Jul; 75(1):20-25. PubMed ID: 28435086
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of inpatients Clostridium difficile prevalence and risk factors in Cameroon.
Djuikoue IC; Tambo E; Tazemda G; Njajou O; Makoudjou D; Sokeng V; Wandji M; Tomi C; Nanfack A; Dayomo A; Lacmago S; Tassadjo F; Sipowo RT; Kakam C; Djoko AB; Assob CN; Andremont A; Barbut F
Infect Dis Poverty; 2020 Aug; 9(1):122. PubMed ID: 32867842
[TBL] [Abstract][Full Text] [Related]
11. Clostridium difficile--a spectrum of virulence and analysis of putative virulence determinants in the hamster model of antibiotic-associated colitis.
Borriello SP; Ketley JM; Mitchell TJ; Barclay FE; Welch AR; Price AB; Stephen J
J Med Microbiol; 1987 Aug; 24(1):53-64. PubMed ID: 3612744
[TBL] [Abstract][Full Text] [Related]
12. Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.
Aldape MJ; Heeney DD; Bryant AE; Stevens DL
J Antimicrob Chemother; 2015 Jan; 70(1):153-9. PubMed ID: 25151204
[TBL] [Abstract][Full Text] [Related]
13. Human intestinal enteroids as a model of
Engevik MA; Danhof HA; Chang-Graham AL; Spinler JK; Engevik KA; Herrmann B; Endres BT; Garey KW; Hyser JM; Britton RA; Versalovic J
Am J Physiol Gastrointest Liver Physiol; 2020 May; 318(5):G870-G888. PubMed ID: 32223302
[No Abstract] [Full Text] [Related]
14. Medical microbiology: A toxin contest.
Ballard JD
Nature; 2010 Oct; 467(7316):665-6. PubMed ID: 20930831
[No Abstract] [Full Text] [Related]
15. Immunochromatographic test and ELISA for the detection of glutamate dehydrogenase (GDH) and A/B toxins as an alternative for the diagnosis of Clostridioides (Clostridium) difficile-associated diarrhea in foals and neonatal piglets.
Ramos CP; Lopes EO; Oliveira Júnior CA; Diniz AN; Lobato FCF; Silva ROS
Braz J Microbiol; 2020 Sep; 51(3):1459-1462. PubMed ID: 32363568
[TBL] [Abstract][Full Text] [Related]
16. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A.
Corthier G; Muller MC; Wilkins TD; Lyerly D; L'Haridon R
Infect Immun; 1991 Mar; 59(3):1192-5. PubMed ID: 1900059
[TBL] [Abstract][Full Text] [Related]
17. Effect of sub-MIC concentrations of metronidazole, vancomycin, clindamycin and linezolid on toxin gene transcription and production in Clostridium difficile.
Gerber M; Walch C; Löffler B; Tischendorf K; Reischl U; Ackermann G
J Med Microbiol; 2008 Jun; 57(Pt 6):776-783. PubMed ID: 18480337
[TBL] [Abstract][Full Text] [Related]
18. Protection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.
Marozsan AJ; Ma D; Nagashima KA; Kennedy BJ; Kang YK; Arrigale RR; Donovan GP; Magargal WW; Maddon PJ; Olson WC
J Infect Dis; 2012 Sep; 206(5):706-13. PubMed ID: 22732923
[TBL] [Abstract][Full Text] [Related]
19. Toxin production of Clostridium difficile in sub-MIC of vancomycin and clindamycin alone and in combination with ceftazidime.
Zarandi ER; Mansouri S; Nakhaee N; Sarafzadeh F; Moradi M
Microb Pathog; 2017 Jun; 107():249-253. PubMed ID: 28286152
[TBL] [Abstract][Full Text] [Related]
20. The role of flagella in Clostridium difficile pathogenicity.
Stevenson E; Minton NP; Kuehne SA
Trends Microbiol; 2015 May; 23(5):275-82. PubMed ID: 25659185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
